148 related articles for article (PubMed ID: 2571595)
1. Clinical evidence of the minimal androgenic activity of norgestimate.
Chapdelaine A; Desmarais JL; Derman RJ
Int J Fertil; 1989; 34(5):347-52. PubMed ID: 2571595
[TBL] [Abstract][Full Text] [Related]
2. [Clinical evidence of the minimal androgenic activity of norgestimate].
Chapdelaine A; Desmarais JL; Derman RJ
Rev Fr Gynecol Obstet; 1990 Jun; 85(6):417-21. PubMed ID: 2143845
[TBL] [Abstract][Full Text] [Related]
3. Long-term profile of a new progestin.
Lippman J
Int J Fertil; 1992; 37 Suppl 4():218-22. PubMed ID: 1362189
[TBL] [Abstract][Full Text] [Related]
4. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives.
Anderson FD
Acta Obstet Gynecol Scand Suppl; 1992; 156():15-21. PubMed ID: 1324552
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience with a new norgestimate-containing oral contraceptive.
Huber J
Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of norgestimate, a progestin with minimal androgenic activity.
Phillips A; Hahn DW; McGuire JL
Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1191-6. PubMed ID: 1415445
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. U.S. clinical trials.
Corson SL
Acta Obstet Gynecol Scand Suppl; 1990; 152():25-31. PubMed ID: 2189282
[TBL] [Abstract][Full Text] [Related]
8. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
9. A norgestimate-containing oral contraceptive: review of clinical studies.
Kafrissen ME
Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
[TBL] [Abstract][Full Text] [Related]
10. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
London RS; Chapdelaine A; Upmalis D; Olson W; Smith J
Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with a new norgestimate-containing oral contraceptive.
Huber J
Int J Fertil; 1992; 37 Suppl 1():47-53. PubMed ID: 1347520
[TBL] [Abstract][Full Text] [Related]
12. The androgenicity of oral contraceptives: the young patient's concerns.
Runnebaum B
Int J Fertil; 1992; 37 Suppl 4():211-7. PubMed ID: 1362188
[TBL] [Abstract][Full Text] [Related]
13. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel.
Janaud A; Rouffy J; Upmalis D; Dain MP
Acta Obstet Gynecol Scand Suppl; 1992; 156():33-8. PubMed ID: 1324555
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives.
Coenen CM; Thomas CM; Borm GF; Rolland R
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():92-7. PubMed ID: 8574256
[TBL] [Abstract][Full Text] [Related]
15. Norgestimate. From the laboratory to three clinical indications.
Henzl MR
J Reprod Med; 2001 Jul; 46(7):647-61. PubMed ID: 11499185
[TBL] [Abstract][Full Text] [Related]
16. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
Ylikorkala O; Lim P; Caubel P
Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of the androgenicity of progestins in hormonal therapy in women.
Linn ES
Clin Ther; 1990; 12(5):447-55. PubMed ID: 2268868
[TBL] [Abstract][Full Text] [Related]
18. The relevance of the pharmacologic properties of a progestational agent to its clinical effects as a combination oral contraceptive.
Upton GV; Corbin A
Yale J Biol Med; 1989; 62(5):445-57. PubMed ID: 2534253
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate.
Corson SL
Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1556-61. PubMed ID: 8178906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
